Humana Inc. $HUM Stock Position Raised by Balentine LLC

Balentine LLC raised its position in shares of Humana Inc. (NYSE:HUM) by 26.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,005 shares of the insurance provider’s stock after purchasing an additional 209 shares during the period. Balentine LLC’s holdings in Humana were worth $246,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in HUM. Revolve Wealth Partners LLC bought a new position in shares of Humana in the 4th quarter valued at approximately $202,000. Cambridge Investment Research Advisors Inc. raised its stake in shares of Humana by 3.2% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 4,608 shares of the insurance provider’s stock valued at $1,219,000 after acquiring an additional 145 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in shares of Humana by 1.9% in the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,955 shares of the insurance provider’s stock valued at $3,692,000 after acquiring an additional 256 shares in the last quarter. Teacher Retirement System of Texas raised its stake in shares of Humana by 202.9% in the 1st quarter. Teacher Retirement System of Texas now owns 21,510 shares of the insurance provider’s stock valued at $5,692,000 after acquiring an additional 14,408 shares in the last quarter. Finally, D.A. Davidson & CO. raised its stake in shares of Humana by 50.6% in the 1st quarter. D.A. Davidson & CO. now owns 1,932 shares of the insurance provider’s stock valued at $511,000 after acquiring an additional 649 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

Shares of NYSE:HUM opened at $278.02 on Friday. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $315.35. The firm has a market capitalization of $33.44 billion, a PE ratio of 21.34, a PEG ratio of 1.71 and a beta of 0.42. The business’s 50 day moving average is $281.34 and its 200-day moving average is $259.00. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The firm had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.Humana’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the previous year, the business posted $6.96 EPS. Sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $3.54 annualized dividend and a yield of 1.3%. Humana’s payout ratio is currently 27.17%.

Analysts Set New Price Targets

HUM has been the topic of a number of recent analyst reports. The Goldman Sachs Group initiated coverage on Humana in a research note on Tuesday, October 14th. They issued a “sell” rating and a $235.00 price objective on the stock. Wells Fargo & Company raised their target price on Humana from $344.00 to $347.00 and gave the company an “overweight” rating in a report on Tuesday, October 7th. Truist Financial set a $300.00 target price on Humana in a report on Tuesday, October 14th. Wall Street Zen lowered Humana from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Finally, Morgan Stanley lowered their target price on Humana from $290.00 to $277.00 and set an “equal weight” rating on the stock in a report on Thursday, July 31st. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $297.58.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.